title: Cathepsin K inhibitors and antisclerostin antibodies. The next treatments for osteoporosis?
authors.affiliation: Inserm UMR 1033, université de Lyon, 69437 Lyon, France; Service de rhumatologie et de pathologie osseuse, hôpital E.-Herriot, 5, place d'Arsonval, 69437 Lyon, France. Electronic address: roland.chapurlat@inserm.fr.
authors.forename: Roland
authors.initials: R
authors.lastname: Chapurlat
mesh_terms: D048868:Adaptor Proteins, Signal Transducing; D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D019485:Bone Morphogenetic Proteins / Q000276:immunology*; D056657:Cathepsin K / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D005819:Genetic Markers / Q000276:immunology*; D006801:Humans; D010024:Osteoporosis / Q000188:drug therapy*
chemical_list: D048868:Adaptor Proteins, Signal Transducing; D000911:Antibodies, Monoclonal; D050071:Bone Density Conservation Agents; D019485:Bone Morphogenetic Proteins; D005819:Genetic Markers; C422903:SOST protein, human; D056657:Cathepsin K
keywords: Antisclerostin; Cathepsin K; Odanacatib; Osteoporosis; Romosozumab